Histogen Welcomes Dr. Hyma Gollamudi as Chief Business Officer

Share Article

Regenerative Medicine Company Poised for Business Growth

I am excited to work toward forming alliances, navigating products through reimbursement hurdles, and contributing to the Company's success in various markets.

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that Dr. Hyma Gollamudi has joined the Company as Chief Business Officer. Gollamudi's business and product development expertise will be invaluable as Histogen begins seeking strategic alliances nationally and internationally.

"With our early-stage product launches underway, and exciting projects coming quickly down the pipeline, Histogen is increasingly examining relationships with companies, physicians and investors," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am excited to welcome Hyma Gollamudi to Histogen, and look forward to seeing the Company's business development and strategic planning efforts flourish through her oversight and experience."

Dr. Gollamudi brings more than 10 years of experience from the healthcare and financial industries to Histogen. Most recently, she served as a Product Director in the healthcare division of Fair Isaac Corporation, a leading provider of analytics and decision management technology. In this position, Dr. Gollamudi oversaw alliances and partnerships and grew the Company's government (Medicare and Medicaid) and commercial business through dedicated attention to client relationships and client managements.

Dr. Gollamudi has authored a number of papers, presented at various healthcare conferences and working groups, and is the co-inventor on two patents. She holds a doctorate in Agricultural Economics from the Ohio State University.

"Histogen's broad range of product applications from a single technology platform is intriguing, and offers almost limitless opportunities in markets from research tools to cosmetics," said Gollamudi. "I am excited to work toward forming alliances, navigating products through reimbursement hurdles, and contributing to the Company's success in various markets."

Through the Company's proprietary bioreactor technology, Histogen is uniquely capable of simulating the embryonic environment, creating products that are embryonic in nature without containing embryonic stem cells or animal components. From two product families - ExCeltrixTM, Histogen's insoluble human Extracellular Matrix (ECM), and ReGenicaTM, Histogen's proprietary liquid complex - the Company has created a product portfolio which includes applications from stem cell culturing to skin care, tissue regeneration to hair regrowth.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high-value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen recently launched its first product - BioNuesisTM Human Stem Cell Culturing Kits - and announced the creation of its cosmeceutical venture - Histogen Aesthetics. For more information, please visit http://www.histogeninc.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eileen Naughton Brandt
Visit website